LIPOPROTEIN(α) IN HEALTH AND DISEASE |
| |
| Authors: | CD Byrne MRCP PhD SH Wild MRCP MRCGP |
| |
| Institution: | 1. Falk Cardiovascular Research Center, Stanford University School of Medicine, Stanford, California;2. Stanford Center for Research in Disease Prevention, Stanford, California |
| |
| Abstract: | SUMMARY Elevated plasma levels of Lp(a) do seem to influence the progression of atherosclerosis. Evidence is emerging that certain apo(a) isoforms may be more atherogenic than others, and in transgenic mice free apo(a) has been shown to be associated with accelerated atherosclerosis. Currently it is not known whether treating elevated Lp(a) levels will reduce progression of atherosclerosis and, as therapeutic options are limited, mass screening of Lp(a) levels in populations is not indicated. The presence of raised Lp(a) levels, however, warrants aggressive treatment to reduce other cardiovascular risk factors. Continuing research to investigate the relationship of the apo(a) gene to other genes, including the plasminogen gene and apo(a)-related genes, will add further information pertaining to the evolution, function, regulation and clinical implications of Lp(a). |
| |
| Keywords: | |
|
|
